Loading
Greenwich LifeSciences, Inc. Stock: price and insider trades · United States
1 insider bought €85k of shares over the last 90 days, the latest by Patel Snehal, filed 30 Jul 2026.
Greenwich LifeSciences, Inc.: what insiders have been doing
Greenwich LifeSciences, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). From 22 October 2025 to 22 October 2026, the disclosure feed for Greenwich LifeSciences, Inc. logged 13 filings by 1 insider.
No insider sold shares on the market over the period. Instead, the filings list 13 purchases totalling €505k, made by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 1 chief executive. Patel Snehal filed the largest purchase, €78k, on 5 January 2026.
With 13 filings in twelve months, the company is quieter than the median of 19 filings across the 5,814 companies we follow on the same exchange. Our records for Greenwich LifeSciences, Inc. go back to 2021, with 106 purchases and no sales on the open market in total. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -19.4 m USD.
The clock since the last published purchase (30 July 2026) now reads 83 days. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
106
Thresholds
n/a
Buy Volume
€6M
106 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleSnehal Patel23 buys
Jaye Thompson1 buy
Since the insiders bought
- +9.9%Entry US$13.50 · Close 16 Oct 2026 US$14.83
- -20.9%Entry US$13.09 · Close at T+365 US$10.35
- -27.6%Entry US$15.87 · Close at T+365 US$11.49
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$15.32
Analyst consensus
2 analysts1.00/5
US$45.00Target US$57.00(+272%)US$69.00
Income statement
EBITDA-US$19.4M
Net income-US$19.4M0.0% margin
Valuation
P/Book72.3x
Beta1.46
Balance sheet & cash
Market capUS$224.9M
Free Cash Flow-US$9.9M
Profitability & ownership
ROE-986.3%
ROA-236.0%
% insiders47.9%
% institutions12.3%
Last declaration on 30 July 2026
Declarations106 total
1,500 shares@ US$13.590.0077% mcap0.3% of flowCommon StockSEC:0001493152-26-035310:0
Canonical exit: 26 Oct 2026 (T+90)
700 shares@ US$13.100.0034% mcap0.1% of flowCommon StockSEC:0001493152-26-035310:1
Canonical exit: 27 Oct 2026 (T+90)
1,500 shares@ US$13.620.0077% mcap0.3% of flowCommon StockSEC:0001493152-26-035085:0
Canonical exit: 25 Oct 2026 (T+90)
2,500 shares@ US$13.140.012% mcap0.5% of flowCommon StockSEC:0001493152-26-034675:0
Canonical exit: 21 Oct 2026 (T+90)
1,100 shares@ US$12.880.0053% mcap0.2% of flowCommon StockSEC:0001493152-26-034675:1
Canonical exit: 22 Oct 2026 (T+90)
1,800 shares@ US$29.830.8% of flowCommon StockSEC:0001493152-26-002319:0
Canonical exit: 13 Apr 2026 (T+90)
2,900 shares@ US$27.541.2% of flowCommon StockSEC:0001493152-26-002112:0
Canonical exit: 12 Apr 2026 (T+90)
4,300 shares@ US$21.361.3% of flowCommon StockSEC:0001493152-26-000229:0
Canonical exit: 31 Mar 2026 (T+90)
2,900 shares@ US$21.730.9% of flowCommon StockSEC:0001493152-26-000006:0
Canonical exit: 30 Mar 2026 (T+90)
4,100 shares@ US$12.620.7% of flowCommon StockSEC:0001493152-25-028424:0
Canonical exit: 18 Mar 2026 (T+90)
4,600 shares@ US$8.370.6% of flowCommon StockSEC:0001493152-25-025282:0
Canonical exit: 23 Feb 2026 (T+90)
10,600 shares@ US$8.431.3% of flowCommon StockSEC:0001493152-25-021614:0
Canonical exit: 5 Feb 2026 (T+90)
2,300 shares@ US$9.260.3% of flowCommon StockSEC:0001493152-25-020675:0
Canonical exit: 29 Jan 2026 (T+90)
3,600 shares@ US$9.880.5% of flowCommon StockSEC:0001641172-25-006555:0
Canonical exit: 24 Jul 2025 (T+90)
5,400 shares@ US$8.980.7% of flowCommon StockSEC:0001641172-25-005606:0
Canonical exit: 16 Jul 2025 (T+90)
3,600 shares@ US$9.100.5% of flowCommon StockSEC:0001641172-25-003118:0
Canonical exit: 6 Jul 2025 (T+90)
5,500 shares@ US$8.730.7% of flowCommon StockSEC:0001641172-25-002921:0
Canonical exit: 3 Jul 2025 (T+90)
2,500 shares@ US$12.510.5% of flowCommon StockSEC:0001493152-25-001842:0
Canonical exit: 10 Apr 2025 (T+90)
1,100 shares@ US$13.310.2% of flowCommon StockSEC:0001493152-25-001298:0
Canonical exit: 6 Apr 2025 (T+90)
3,400 shares@ US$12.950.7% of flowCommon StockSEC:0001493152-25-001103:0
Canonical exit: 3 Apr 2025 (T+90)
2,000 shares@ US$11.970.4% of flowCommon StockSEC:0001493152-25-000350:0
Canonical exit: 2 Apr 2025 (T+90)
2,400 shares@ US$11.360.4% of flowCommon StockSEC:0001493152-25-000151:0
Canonical exit: 31 Mar 2025 (T+90)
3,200 shares@ US$11.120.6% of flowCommon StockSEC:0001493152-25-000005:0
Canonical exit: 30 Mar 2025 (T+90)
1,000 shares@ US$12.918.6% of flowCommon StockSEC:0001493152-24-047527:0
Canonical exit: 19 Feb 2025 (T+90)
1,500 shares@ US$14.630.3% of flowCommon StockSEC:0001493152-24-038657:0
Canonical exit: 25 Dec 2024 (T+90)
25 of 106 declarations
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a United States-based clinical-stage biopharmaceutical company headquartered in the Houston, Texas area. Its business is highly focused: the company is developing GP2, a peptide immunotherapy designed to help prevent breast cancer recurrence in selected HER2/neu-positive patients. Greenwich LifeSciences refers to the GP2 plus GM-CSF combination as GLSI-100, which is the centerpiece of its clinical strategy and the asset around which investor attention is currently concentrated.
The company’s history is typical of a specialty biotech built around a single lead program. Rather than operating a broad commercial portfolio, Greenwich LifeSciences has pursued a focused development path aimed at advancing GLSI-100 through late-stage clinical evaluation and, ultimately, toward potential regulatory submission. Its flagship trial, FLAMINGO-01, is a global Phase III study designed to assess the safety and efficacy of GLSI-100 in HER2-positive breast cancer patients who have completed standard trastuzumab-based therapy. According to company disclosures, the trial is enrolling at up to 150 sites globally, underscoring the operational scale of the program.
Read moreShow less
From a market-positioning perspective, Greenwich LifeSciences competes in a crowded and scientifically demanding oncology landscape. The target setting—HER2-positive breast cancer recurrence prevention—includes established therapies from large multinational pharmaceutical companies and a high evidentiary bar for any new entrant. Greenwich’s competitive angle is not breadth, but specificity: it is betting on a differentiated immunotherapy approach in a well-defined patient segment. That makes the investment case relatively easy to understand but also inherently binary, as value creation depends heavily on clinical execution, trial outcomes, and regulatory progress.
Several recent corporate developments are relevant for investors. In 2025, the company announced that GLSI-100 received U.S. FDA Fast Track designation in the HLA-A*02 population, a meaningful regulatory milestone that can facilitate more frequent interactions with the FDA and potentially speed development. Greenwich also said it was building out an internal clinical operations team to reduce reliance on external CROs and improve efficiency as FLAMINGO-01 expands. In 2026, the company continued to update investors on its annual filing status and financing strategy, highlighting the ongoing capital requirements of a Phase III oncology program.
For French-speaking investors in Europe, Greenwich LifeSciences is best viewed as a narrowly focused NASDAQ-listed biotechnology company in the United States, with a single leading asset, clear clinical ambition, and substantial execution and financing risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
